Antitumor activity in A2780 ovarian cancer cells

Antitumor activity in A2780 ovarian cancer cells is not a specific molecular target, such as a receptor or enzyme, but rather a description of a biological effect or an experimental assay result. The A2780 cell line is a commonly used human ovarian carcinoma model derived from an untreated patient, frequently employed in oncology research to evaluate the cytotoxicity and antiproliferative potential of novel drug candidates (Sigma-Aldrich, 2023). When a compound is described as having antitumor activity in these cells, it indicates that the substance successfully induces cell death or inhibits growth within this specific cellular context (PubMed, PMID: 6314253). Because this term refers to a phenotypic outcome in a laboratory model rather than a defined biological entity, it does not meet the criteria for a therapeutic target. Consequently, it lacks specific molecular classifications, biochemical mechanisms of action, or direct drug interactions associated with a single protein or gene. Researchers often use this cell line to study mechanisms of drug resistance, particularly to platinum-based therapies, making it a staple in preclinical oncology studies (PubMed, PMID: 3001438).